Clearance of amyloid-β peptides by microglia and macrophages: The issue of what, when and where

Future Neurology

Volumn 7, Issue 2, 2012, Pages 165-176

  Lai, Aaron Y ^a   McLaurin, Joanne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; amyloid b peptide; macrophages; microglia; perivascular macrophages; phagocytosis

Indexed keywords

AMYLOID BETA PROTEIN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AGING; ALZHEIMER DISEASE; CELL ACTIVATION; CELL FUNCTION; CELL PHAGOCYTOSIS; CELL POPULATION; CELLULAR DISTRIBUTION; HUMAN; MACROPHAGE FUNCTION; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84858259145     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.6     Document Type: Review

References (105)

1. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9(5), 387-398 (2010).
2. Wenk GL. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 64(Suppl. 9), 7-10 (2003). (Pubitemid 37040372)
3. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283(44), 29615-29619 (2008).
4. Mohamed A, Cortez L, de Chaves EP. Aggregation state and neurotoxic properties of alzheimer b-amyloid peptide. Curr. Protein. Pept. Sci. 12(3), 235-257 (2011).
5. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J. Med. 77(1), 69-81 (2010).
6. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880), 535-539 (2002). (Pubitemid 34288854)
7. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008).
8. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132(1), 86-101 (1988).
9. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 77(6), 569-575 (1989). (Pubitemid 19125369)
10. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24(3), 173-182 (1989). (Pubitemid 19271472)
11. el Hachimi KH, Foncin JF. Do microglial cells phagocyte the beta/A4-amyloid senile plaque core of Alzheimer disease? C. R. Acad. Sci. III 317(5), 445-451 (1994). (Pubitemid 24193173)
12. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11(11), 723-737 (2011).
13. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119-145 (2009).
14. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 75(3), 388-397 (2004). (Pubitemid 38316367)
15. Dalkara T, Gursoy-Ozdemir Y, Yemisci M. Brain microvascular pericytes in health and disease. Acta Neuropathol. 122(1), 1-9 (2011).
16. Sedgwick JD, Schwender S, Imrich H, Dörries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl Acad. Sci. USA 88(16), 7438-7442 (1994).
17. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10(11), 1387-1394 (2004). (Pubitemid 350014685)
18. de Haas AH, Boddeke HW, Biber K. Region-specific expression of Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9(5), 387-398 (2010).
19. Wenk GL. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 64(Suppl. 9), 7-10 (2003). (Pubitemid 37040372)
20. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283(44), 29615-29619 (2008).
21. Mohamed A, Cortez L, de Chaves EP. Aggregation state and neurotoxic properties of alzheimer b-amyloid peptide. Curr. Protein. Pept. Sci. 12(3), 235-257 (2011).
22. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J. Med. 77(1), 69-81 (2010).
23. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880), 535-539 (2002). (Pubitemid 34288854)
24. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008).
25. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132(1), 86-101 (1988).
26. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 77(6), 569-575 (1989). (Pubitemid 19125369)
27. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24(3), 173-182 (1989). (Pubitemid 19271472)
28. el Hachimi KH, Foncin JF. Do microglial cells phagocyte the beta/A4-amyloid senile plaque core of Alzheimer disease? C. R. Acad. Sci. III 317(5), 445-451 (1994). (Pubitemid 24193173)
29. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11(11), 723-737 (2011).
30. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119-145 (2009).
31. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 75(3), 388-397 (2004). (Pubitemid 38316367)
32. Dalkara T, Gursoy-Ozdemir Y, Yemisci M. Brain microvascular pericytes in health and disease. Acta Neuropathol. 122(1), 1-9 (2011).
33. Sedgwick JD, Schwender S, Imrich H, Dörries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl Acad. Sci. USA 88(16), 7438-7442 (1994).
34. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10(11), 1387-1394 (2004). (Pubitemid 350014685)
35. de Haas AH, Boddeke HW, Biber K. Region-specific expression of immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 20(3), 426-433 (2006).
36. Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS ONE 6(8), e23789 (2011).
37. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-919 (2000). (Pubitemid 30644751)
38. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24(27), 6144-6151 (2004). (Pubitemid 38891105)
39. Zhang L, Fiala M, Cashman J, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 10(1), 1-7 (2006). (Pubitemid 44401358)
40. Yanagisawa D, Shirai N, Amatsubo T, et al. Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 31(14), 4179-4185 (2010).
41. Hawkes CA, Deng L, Fenili D, Nitz M, McLaurin J. In vivo uptake of beta-amyloid by non-plaque associated microglia. Curr. Alzheimer Res. (2011) (Epub ahead of print).
42. Heppner FL, Greter M, Marino D, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11(2), 146-152 (2005). (Pubitemid 40321349)
43. Gowing G, Vallires L, Julien JP. Mouse model for ablation of proliferating microglia in acute CNS injuries. Glia 53(3), 331-337 (2006). (Pubitemid 43221354)
44. Grathwohl SA, Klin RE, Bolmont T, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 12(11), 1361-1363 (2009).
45. Rezai-Zadeh K, Gate D, Gowing G, Town T. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 8(2), 156-163 (2011).
46. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 117(8), 949-960 (2010).
47. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49(4), 489-502 (2006). (Pubitemid 43221886)
48. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239(4837), 290-292 (1988). (Pubitemid 18061496)
49. Malm TM, Koistinaho M, Prepalo M, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18(1), 134-142 (2005). (Pubitemid 40092904)
50. Stalder AK, Ermini F, Bondolfi L, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25(48), 11125-11132 (2005). (Pubitemid 43089557)
51. Mildner A, Schmidt H, Nitsche M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 10(12), 1544-1553 (2007). (Pubitemid 350175884)
52. Mildner A, Schlevogt B, Kierdorf K, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31(31), 11159-11171 (2011).
53. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10(12), 1538-1543 (2007). (Pubitemid 350175883)
54. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220(3), 640-646 (2001). (Pubitemid 32799969)
55. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl Acad. Sci. USA 103(31), 11719-11723 (2006). (Pubitemid 44182517)
56. Jordão JF, Ayala-Grosso CA, Markham K, et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS ONE 5(5), e10549 (2010).
57. Burgess A, Ayala-Grosso CA, Ganguly M, Jordão JF, Aubert I, Hynynen K. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS ONE 6(11), e27877 (2011).
58. Ueno M, Nakagawa T, Wu B, et al. Transporters in the brain endothelial barrier. Curr. Med. Chem. 17(12), 1125-1138 (2010).
59. Attems J, Jellinger K, Thal DR, van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 37(1), 75-93 (2011).
60. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl Acad. Sci. USA 106(4), 1261-1266 (2009).
61. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29(6), 313-326 (2009).
62. Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 31(16), 6208-6220 (2011).
63. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13(4), 432-438 (2007). (Pubitemid 46559828)
64. Yamamoto M, Horiba M, Buescher JL, et al. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol. 166(5), 1475-1485 (2005). (Pubitemid 40586517)
65. Kiyota T, Yamamoto M, Xiong H, et al. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4(7), e6197 (2009).
66. Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 177(5), 2549-2562 (2010).
67. Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-b phagocytosis. J. Neurosci. 30(50), 17091-17101 (2010).
68. Fuhrmann M, Bittner T, Jung CK, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 13(4), 411-413 (2010).
69. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28(25), 6333-6341 (2008).
70. Wyss-Coray T, Yan F, Lin AH, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99(16), 10837-10842 (2002).
71. Huang SM, Mouri A, Kokubo H, et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281(26), 17941-17951 (2006). (Pubitemid 44035593)
72. Madani R, Poirier R, Wolfer DP, et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J. Neurosci. Res. 84(8), 1871-1878 (2006). (Pubitemid 44892621)
73. Farris W, Schtz SG, Cirrito JR, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171(1), 241-251 (2007). (Pubitemid 47339241)
74. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23(6), 1992-1996 (2003). (Pubitemid 36368884)
75. Iwata N, Mizukami H, Shirotani K, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 24(4), 991-998 (2004). (Pubitemid 38146610)
76. Miners JS, Barua N, Kehoe PG, Gill S, Love S. Ab-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70(11), 944-959 (2011).
77. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28(33), 8354-8360 (2008).
78. Mohamed A, Posse de Chaves E. Ab internalization by neurons and glia. Int. J. Alzheimers Dis. 2011, 127984 (2011).
79. Huang F, Buttini M, Wyss-Coray T, et al. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am. J. Pathol. 155(5), 1741-1747 (1999).
80. Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl Acad. Sci. USA 107(48), 20816-20821 (2010).
81. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of Toll-like receptor signalling in Abeta uptake and clearance. Brain 129(Pt 11), 3006-3019 (2006). (Pubitemid 44684521)
82. Song M, Jin J, Lim JE, et al. TLR4 mutation reduces microglial activation, increases Ab deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation 8, 92 (2011).
83. Richard KL, Filali M, Prfontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 28(22), 5784-5793 (2008).
84. Michaud JP, Richard KL, Rivest S. MyD88-adaptor protein acts as a preventive mechanism for memory deficits in a mouse model of Alzheimer's disease. Mol. Neurodegener. 6(1), 5 (2011).
85. Lim JE, Kou J, Song M, et al. MyD88 deficiency ameliorates b-amyloidosis in an animal model of Alzheimer's disease. Am. J. Pathol. 179(3), 1095-1103 (2011).
86. Tan J, Town T, Mori T, et al. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J. Neurosci. 20(20), 7587-7594 (2000).
87. Townsend KP, Vendrame M, Ehrhart J, et al. CD45 isoform RB as a molecular target to oppose lipopolysaccharide-induced microglial activation in mice. Neurosci. Lett. 362(1), 26-30 (2004). (Pubitemid 38638377)
88. Zhu Y, Hou H, Rezai-Zadeh K, et al. CD45 deficiency drives amyloid-peptide oligomers and neuronal loss in Alzheimer's disease mice. J. Neurosci. 31(4), 1355-1365 (2011).
89. Townsend KP, Town T, Mori T, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur. J. Immunol. 35(3), 901-910 (2005). (Pubitemid 40425546)
90. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286(5448), 2352-2355 (1999). (Pubitemid 30016899)
91. Tan J, Town T, Crawford F, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5(12), 1288-1293 (2002). (Pubitemid 35417763)
92. Keene CD, Chang RC, Lopez-Yglesias AH, et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am. J. Pathol. 177(1), 346-354 (2010).
93. Shie FS, Breyer RM, Montine TJ. Microglia lacking E Prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am. J. Pathol. 166(4), 1163-1172 (2005). (Pubitemid 40524440)
94. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14(6), 681-687 (2008). (Pubitemid 351809551)
95. Salins P, He Y, Olson K, Glazner G, Kashour T, Amara F. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer's disease and causes neuronal apoptosis. Neurosci. Lett. 430(1), 81-86 (2008).
96. Wyss-Coray T, Lin C, Yan F, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7(5), 612-618 (2001). (Pubitemid 32448330)
97. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia 45(2), 208-212 (2004). (Pubitemid 38196997)
98. Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 56(10), 1048-1060 (2008).
99. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 118(4), 475-485 (2009).
100. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23(4), 159-169 (2004). (Pubitemid 38980441)
101. Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci. 29(9), 506-510 (2006). (Pubitemid 44291814)
102. Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 45(1), 75-88 (2004). (Pubitemid 38076230)
103. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging 33(1), 195.e1-12 (2010).
104. Rolyan H, Scheffold A, Heinrich A, et al. Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. Brain 134(Pt 7), 2044-2056 (2011).
105. Clinical Trials Database. http://clinicaltrials.gov/ct2/show/nct014734 85?term=ultrasound+mri+brain+tumorära nk=2